Luye Pharma Group Ltd.
Luye Pharma Group Ltd. Fundamental Analysis
Luye Pharma Group Ltd. (LYPHF) shows weak financial fundamentals with a PE ratio of 17.76, profit margin of 9.81%, and ROE of 3.99%. The company generates $6.2B in annual revenue with weak year-over-year growth of -1.33%.
Key Strengths
Areas of Concern
The stock receives a Fundamental Health Score of 32.1/100 based on profitability, valuation, growth, and balance sheet metrics. The F grade reflects weak fundamentals and significant financial concerns.
Fundamental Health Score
We analyze LYPHF's fundamental strength across five key dimensions:
Efficiency Score
WeakLYPHF struggles to generate sufficient returns from assets.
Valuation Score
ExcellentLYPHF trades at attractive valuation levels.
Growth Score
WeakLYPHF faces weak or negative growth trends.
Financial Health Score
ExcellentLYPHF maintains a strong and stable balance sheet.
Profitability Score
WeakLYPHF struggles to sustain strong margins.
Key Financial Metrics
Is LYPHF Expensive or Cheap?
P/E Ratio
LYPHF trades at 17.76 times earnings. This indicates a fair valuation.
PEG Ratio
When adjusting for growth, LYPHF's PEG of 0.00 indicates potential undervaluation.
Price to Book
The market values Luye Pharma Group Ltd. at 0.68 times its book value. This may indicate undervaluation.
EV/EBITDA
Enterprise value stands at 2.89 times EBITDA. This is generally considered low.
How Well Does LYPHF Make Money?
Net Profit Margin
For every $100 in sales, Luye Pharma Group Ltd. keeps $9.81 as profit after all expenses.
Operating Margin
Core operations generate 19.59 in profit for every $100 in revenue, before interest and taxes.
ROE
Management delivers $3.99 in profit for every $100 of shareholder equity.
ROA
Luye Pharma Group Ltd. generates $1.87 in profit for every $100 in assets, demonstrating efficient asset deployment.
Following the Money - Real Cash Generation
Operating Cash Flow
Luye Pharma Group Ltd. generates strong operating cash flow of $2.32B, reflecting robust business health.
Free Cash Flow
Luye Pharma Group Ltd. generates strong free cash flow of $630.21M, providing ample flexibility for dividends, buybacks, or growth.
FCF Per Share
Each share generates $0.16 in free cash annually.
FCF Yield
LYPHF converts 5.93% of its market value into free cash.
Financial Ratios Analysis
Valuation Ratios
P/E Ratio
Price to earnings ratio
17.76
vs 25 benchmark
PEG Ratio
Price/earnings to growth ratio
0.003
vs 25 benchmark
P/B Ratio
Price to book value ratio
0.68
vs 25 benchmark
P/S Ratio
Price to sales ratio
1.72
vs 25 benchmark
Financial Health
Debt/Equity
Total debt to shareholders' equity
0.59
vs 25 benchmark
Current Ratio
Current assets to current liabilities
1.53
vs 25 benchmark
Efficiency Ratios
ROE
Return on equity percentage
0.04
vs 25 benchmark
ROA
Return on assets percentage
0.02
vs 25 benchmark
ROCE
Return on capital employed
0.05
vs 25 benchmark
How LYPHF Stacks Against Its Sector Peers
| Metric | LYPHF Value | Sector Average | Performance |
|---|---|---|---|
| P/E Ratio | 17.76 | 28.92 | Better (Cheaper) |
| ROE | 3.99% | 643.00% | Weak |
| Net Margin | 9.81% | -45024.00% (disorted) | Weak |
| Debt/Equity | 0.59 | 0.34 | Weak (High Leverage) |
| Current Ratio | 1.53 | 4.50 | Neutral |
| ROA | 1.87% | -16474.00% (disorted) | Weak |
LYPHF outperforms its industry in 1 out of 6 key metrics, but lagging in ROE.
Historical Growth Performance
5-Year Growth Trajectory
This section reviews Luye Pharma Group Ltd.'s 5-year compound annual growth rate (CAGR) and compares its performance against the typical investment style of its industry.
Revenue CAGR
-18.81%
Industry Style: Defensive, Growth, Innovation
DecliningEPS CAGR
-72.64%
Industry Style: Defensive, Growth, Innovation
DecliningFCF CAGR
-91.81%
Industry Style: Defensive, Growth, Innovation
Declining